As we approach the end of 2023, it's a fitting time to reflect on Occuity's progress throughout the year. Looking back, it's clear that this has been our busiest year yet. Our team has grown, and we've achieved milestones across all aspects of the business. In this blog post, we will delve into the highlights and accomplishments that have shaped Occuity's success over the past year.
Unveiled the AX1 Axiometer™ prototype at 100% Optical - The event was a major success and allowed the team to highlight our innovative technology and connect with industry professionals.
PM1 Pachymeter clinical trials completed - results published in the prestigious Journal of Ophthalmic & Physiological Optics (OPO) with the PM1 performance being excellent and comparable to current market options.
Awarded Innovate UK grant - used to support FDA approval efforts for the PM1 Pachymeter and to accelerate growth activities across the company.
Passed ISO 13845 audit - with no major or minor faults, the certification recognises our commitment to quality management systems in the development and manufacturing of medical devices.
PM1 Pachymeter submitted for CE marking - a critical milestone in launching the PM1 in European markets and is a testament to our commitment to delivering the highest quality product in full compliance with regulations and standards.
Finalist for Hard Tech Investment of the Year at UK Business Angels Association - acknowledges pioneering founders and early-stage investors transforming research-intensive sectors and driving the future economy.
Attended the 41st ESCRS Congress in Vienna - an opportunity which allowed the team to build new connections in the industry and enhance our global network of distributors.
PM1 submitted for FDA 510 (K) mark - represents a critical milestone in launching the PM1 in the US market and demonstrates that the device to be marketed is safe and effective.
Shortlisted for Health Technology Award - the technology and innovation behind the AX1 earned us a coveted spot at the prestigious IET Excellence and Innovation Awards.
Built a network of distribution partners ahead of the launch of PM1 in 2024.
Exciting first results from Occuity ‘SD1’ diabetes screening prototype - accelerated by the recent Innovate UK Biomedical Catalyst grant, the team has already collected data that shows promising outcomes.
Attended the American Academy of Ophthalmology (AAO) Annual Meeting in San Francisco - this event was truly significant as it was the debut of the AX1 prototype.
Awarded Institute of Physics Business Start-up Award - this prestigious award is a recognition of our commitment to tackling some of humanity's greatest healthcare challenges through the development of a truly innovative optical technology platform.
Two patent milestones reached - successfully filed a new patent application and also had a key patent granted. As a highly innovative company, our intellectual property is key to ensuring our commercial success and device developments.
Closed a £1.3m Convertible Loan Note investment round to enable us to continue our growth ahead of generating our first revenues in 2024.
As we sign off on 2023, the Occuity team just wants to say a big thank you to everyone who has been a part of the journey. Whether you're an investor, an industry professional, or a follower on our social media channels, we thank you. Reflecting on our achievements, it is evident that we have accomplished quite a bit in the past year. As we gear up for the launch of our first device to market, we anticipate that 2024 will be equally exciting, marked by continued growth across all facets of our business and the continued attraction of passionate talent aligned with our mission.
We hope you all have a Merry Christmas and a Happy New Year!